NR 566 Midterm Study Guide

NR 566 Midterm Study Guide Week 1 -Things to know about each of the major antibiotic drug classes Bactericidal vs. Bacteriostatic • Bactericidal antibiotics directly kill bacteria o preferred for immunocompromised patients such as those with diabetes, HIV, or cancer & for those who have overwhelming infections. o Agents: aminoglycosides, beta-lactams, fluoroquinolones, metronidazole, most antimycobacterial agents, streptogramins, & vancomycin. • Bacteriostatic agents inhibit bacterial proliferation while the host's immune system does the killing. o Agents: clindamycin, macrolides, sulfonamides, & tetracyclines o Bactericidal agents: “BANG Q R.I.P” - Beta-lactams, Aminoglicosides, Nitroimidazoles (Metronidazole), Glycopeptides (Vancomycin), Quinolones, Rifampicin, Polymyxins (Colistin) o Bacteriostatic agents: “Ms. Colt” - Macrolides, Sulfonamides, Chloramphenicol, Oxazolidinones, Lincosamides (Clindamycin), Tetracyclines *Bactericidal antibiotics kill bacteria directly, & bacteriostatic antibiotics stop/weaken bacteria from growing to enable the immune system to take hold of infection* Aminoglycosides (narrow-spectrum antibiotics used primarily against aerobic gram-negative bacilli; disrupt protein synthesis by binding to the 30S ribosomal subunit, resulting in rapid bacterial death) (p. 683) • Examples: Gentamicin, Tobramycin, Amikacin, Neomycin, Kanamycin, Streptomycin, Paromycin, Plazomicin (p. 687) • Indications for use: Treatment of serious infections caused by gram-negative aerobic bacilli (Pseudomonas aeruginosa, enterobacteriaceae, topical infection, ocular bacterial infections, intestinal amebiasis, complicated UTI) (p. 687) • Contraindications & high-risk patients: Aminoglycosides should be used with caution in patients with renal impairment, preexisting hearing impairment, & those receiving ototoxic & nephrotoxic drugs. (pp. 685-687) • Monitoring needs: Aminoglycoside levels (peaks & troughs) & renal function must be monitored. Monitor for neurotoxicity, ototoxicity, & nephrotoxicity. • Which ones require renal dosing adjustments and how much (i.e., 25%, 50%, etc.): To avoid serious toxicity, we must reduce dosage size or increase the dosing interval in patients with kidney disease. (p. 685) *Clarithromycin • Patient education: *Patients should be informed about the symptoms of vestibular & cochlear damage & instructed to report them. • Lifespan considerations: (p. 685) Infants: Aminoglycosides are approved to treat bacterial infections in infants younger than 8 days. Dosing is based on weight & length of gestation. Children/adolescents: Aminoglycosides are safe for use against bacterial infections in children & adolescents. Pregnant women: There is evidence that use of aminoglycosides in pregnancy can harm the fetus. Breastfeeding women: Gentamicin is probably safe to use during lactation. There is limited information regarding its use in this way. Older adults: Caution must be used regarding decreased renal function in the older adult. Cephalosporins (Beta-lactam antibiotics similar in structure & actions to the penicillins; bactericidal; often resistant to beta-lactamases, & active against a broad spectrum of pathogens; most widely used group of antibiotics) (p. 669) • Examples: 1st generation: Cephalexin (Keflex); 2nd generation: Cefoxitin, Cefaclor (Ceclor); 3rd generation: Cefotaxime, Cefdinir, Ceftriaxone (Rocephin); 4th generation: Cefepime, 5th generation: Ceftaroline • Indications for use: 1st generation: Staphylococci or streptococci (Use in patients with mild PCN allergy, strep pharyngitis, skin infections, & surgical prophylaxis) 2nd generation: Haemophilus influenzae, Klebsiella, pneumococci, & staphylococci (Otitis, sinusitis, & respiratory tract infections) 3rd generation: Pseudomonas aeruginosa, Neisseria gonorrhoeae, & Klebsiella, Serratia (Meningitis, gram- negative nosocomial infections) 4th generation: Pseudomonas aeruginosa (Hospital-acquired pneumonia & complicated intra-abdominal & UTIs due to resistant pseudomonas) 5th generation: Methicillin-resistant Staphylococcus aureus (MRSA-associated infections). (p. 671) • Contraindications & high-risk patients: Cephalosporins are contraindicated for patients with a history of allergic reactions to cephalosporins or severe reactions to penicillin. Patients using cefazolin & cefotetan must not consume alcohol. Use cefotetan, cefazolin, & ceftriaxone cautiously in patients taking other agents that also promote bleeding (anticoagulants, thrombolytics, NSAIDS, etc). (pp. 670-671) • Monitoring needs: Monitor for signs of C. dif infection & renal function in patients with renal impairment and/or prolonged use. • Which ones require renal dosing adjustments and how much (i.e., 25%, 50%, etc.): In patients with renal insufficiency, dosages of most cephalosporins must be reduced to prevent accumulation to toxic levels. (EXCEPTION: Ceftriaxone (3rd generation) is eliminated largely by the liver, so dosage reduction is unnecessary in patients with renal impairment) (p. 669) • Patient education: *All cephalosporins can promote C. dif infection, so patients should be instructed to report an increase in stool frequency. • Lifespan considerations: Infants: 3rd generation cephalosporins are used to treat bacterial infections in neonates as well as infants. Children/adolescents: Cephalosporins are commonly used to treat bacterial infections in children, including otitis media & gonococcal & pneumococcal infections. Pregnant women: All cephalosporins appear safe for use in pregnancy. Breastfeeding women: Cephalosporins are generally not expected to cause adverse effects in breastfed infants. Older adults: Doses should be adjusted in older adults with decreased renal function.